PacBio Joins Forces to Launch Advanced Genomics Lab in Singapore
Introducing a Breakthrough in Genomics Innovation
In a monumental development for the field of genomics, PacBio (NASDAQ: PACB), together with A*STAR and Macrogen, has officially opened a cutting-edge joint laboratory at the A*STAR Genome Institute of Singapore. This state-of-the-art facility, situated at Biopolis, aims to significantly advance the research community's access to advanced long-read sequencing technologies.
Significance of the Collaboration
The partnership between these leading organizations represents a major leap forward in the application of HiFi long-read sequencing, particularly in the domains of precision medicine, population genomics, and disease biology within Southeast Asia. The laboratory will house two PacBio Revio systems, enhancing the local research ecosystem with top-tier sequencing capabilities facilitated by Macrogen's streamlined services.
Empowering Researchers with Advanced Sequencing Tools
This new laboratory is designed not just as a workspace but as an innovation hub. Researchers at A*STAR GIS will have unparalleled access to leading-edge sequencing tools, expanding their ability to conduct complex genomic research. Dr. Tam Wai Leong, who serves as Deputy Executive at A*STAR GIS, highlighted the importance of this collaboration, noting that it comes at a crucial moment as the utilization of long-read sequencing grows rapidly. This partnership is expected to bolster Singapore's status as a prominent center for genomic research.
Innovating Precision Medicine through HiFi Sequencing
PacBio Revio systems are renowned for their scalability, high throughput, and user-friendly design, equipped with proprietary HiFi sequencing technology that produces highly accurate long reads. These systems are particularly suited for intricate genomic studies, offering advanced features such as real-time methylation detection, which supports comprehensive multi-omics research efforts. The onboard analysis capabilities are further enhanced by DeepConsensus base calling, maximizing research efficiency.
Support for Local Research Initiatives
Jason Kang, the General Manager and Vice President of PacBio APAC, articulated the company’s dedication to facilitating scientific advancements through its innovative sequencing technologies. He noted that establishing this joint lab not only brings HiFi sequencing closer to local researchers but also empowers them to pursue trailblazing projects in various fields, including precision medicine and genomics.
Advancing National Precision Medicine Initiatives
The initiative aims to support multiple facets of Singapore’s National Precision Medicine agenda, offering vital resources for researchers involved in population genetics, cancer studies, and research into rare diseases. The addition of Revio's capabilities is expected to significantly propel projects forward, promoting better health outcomes through enhanced research efforts.
Commitment from Partners
Dr. Chong Hyon-yong, CEO of Macrogen Singapore, stated the pride they felt in being part of such a transformative collaboration. By offering essential sequencing service support, Macrogen contributes to creating a robust genomics ecosystem, ensuring that scientists are equipped to push the boundaries of genomic research and discover breakthroughs that may revolutionize healthcare.
Contact Information for Inquiries
For further inquiries regarding this collaboration, representatives from both PacBio and Macrogen are available for contact. Should you have any questions or require more information, you can reach out to:
Contacts (PacBio)
For investor relations, please contact Todd Friedman at ir@pacificbiosciences.com.
Contacts (Macrogen)
For media requests, reach out to Chloe Je at chloeje@macrogen.com.
Frequently Asked Questions
What is the purpose of the new joint laboratory?
The joint laboratory aims to provide access to advanced long-read sequencing technologies to enhance genomics research capabilities in Singapore.
Who are the partners involved in the laboratory's establishment?
PacBio, A*STAR, and Macrogen are the key collaborators in launching this advanced genomics facility.
What technologies will be available at the lab?
The lab will feature PacBio Revio systems, known for their high quality and accuracy, particularly in complex genomic research.
How will this lab impact precision medicine in the region?
The lab is expected to revolutionize precision medicine practices by enabling deeper insights into disease biology and enhancing research efforts in crucial areas.
Where is the laboratory located?
The laboratory is located at the A*STAR Genome Institute of Singapore, specifically within Biopolis.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.